Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
diphtheria toxoid + tetanus toxoid + acellular pertussis + inactivated poliovirus + recombinant hepatitis B surface antigen
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
A combination vaccine containing **diphtheria toxoid**, **tetanus toxoid**, **acellular pertussis antigens (detoxified pertussis toxin, filamentous hemagglutinin, pertactin, fimbriae types 2 & 3)**, **inactivated poliovirus (types 1, 2, 3)**, and **recombinant hepatitis B surface antigen**, used for active immunization against diphtheria, tetanus (lockjaw), pertussis (whooping cough), hepatitis B, and poliomyelitis in infants and children aged 6 weeks to 6 years[1][2][3][5][6][7]. It works by stimulating the immune system to produce protective antibodies against each pathogen. Pediatric combination vaccines help reduce the number of required injections while providing protection against multiple diseases[6].
- Brand names
- PediarixVaxelis
- Other names
- DTaP-IPV-HepB vaccineDTaP-HepB-IPV vaccineDTP vaccine combined with HepB and IPV
02
Targets
FHA (Filamentous hemagglutinin)FIM2/FIM3 (Fimbriae types 2 and 3)HBsAg (Hepatitis B surface antigen)PRN (Pertactin)Diphtheria toxin
Beyond the preview
Go deeper on diphtheria toxoid + tetanus toxoid + acellular pertussis + inactivated poliovirus + recombinant hepatitis B surface antigen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on diphtheria toxoid + tetanus toxoid + acellular pertussis + inactivated poliovirus + recombinant hepatitis B surface antigen.